ИСТИНА |
Войти в систему Регистрация |
|
ИПМех РАН |
||
Integrated molecular analysis of the LME and genomic alterations provides valuable information about correlative biomarkers for response to CART19 immunotherapy in DLBCL patients. With this cohort, PIK3CA amplification corresponded to improved PFS in DLBCL. We observed increased MHCII expression and centrocyte-like cells in GCB DLBCL CART19 responders, while SMAD1 was higher in ABC responders. Germinal center-like and mesenchymal LME exhibited increased OS, while inflamed and depleted LME subtypes had decreased OS. These genomic biomarkers for CART19 treatment response may help guide clinical treatment plans, minimize adverse events, or develop new therapeutic approaches.